Walleye Capital LLC Buys 34,513 Shares of Amyris, Inc. (NASDAQ:AMRS)

Walleye Capital LLC grew its stake in shares of Amyris, Inc. (NASDAQ:AMRSGet Rating) by 65.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 87,297 shares of the biotechnology company’s stock after acquiring an additional 34,513 shares during the period. Walleye Capital LLC’s holdings in Amyris were worth $161,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Prospera Financial Services Inc bought a new position in shares of Amyris during the 1st quarter valued at approximately $39,000. Pinnacle Wealth Management Advisory Group LLC bought a new position in shares of Amyris during the 1st quarter valued at approximately $44,000. Williams Jones Wealth Management LLC. bought a new position in shares of Amyris during the 1st quarter valued at approximately $45,000. FCA Corp TX bought a new position in shares of Amyris during the 1st quarter valued at approximately $48,000. Finally, Cetera Investment Advisers bought a new position in shares of Amyris during the 1st quarter valued at approximately $67,000. 43.08% of the stock is owned by institutional investors.

Amyris Price Performance

Shares of NASDAQ:AMRS opened at $2.22 on Friday. The firm has a fifty day moving average price of $2.82 and a two-hundred day moving average price of $2.55. Amyris, Inc. has a one year low of $1.44 and a one year high of $7.39. The company has a market cap of $721.92 million, a price-to-earnings ratio of -1.28 and a beta of 1.22.

Analyst Ratings Changes

Several research analysts recently commented on AMRS shares. Piper Sandler raised their price objective on shares of Amyris from $2.50 to $4.00 and gave the stock a “neutral” rating in a report on Monday, September 19th. Cowen cut their price objective on shares of Amyris from $13.00 to $6.00 in a report on Thursday, November 10th. Cowen cut their price objective on shares of Amyris from $13.00 to $6.00 in a report on Thursday, November 10th. Oppenheimer downgraded shares of Amyris from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 9th. Finally, JPMorgan Chase & Co. downgraded shares of Amyris from an “overweight” rating to a “neutral” rating in a report on Thursday, November 10th. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $5.33.

Insider Buying and Selling at Amyris

In other Amyris news, Director Frank Kung sold 1,385,000 shares of the firm’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $4.20, for a total value of $5,817,000.00. Following the completion of the transaction, the director now directly owns 458,591 shares of the company’s stock, valued at approximately $1,926,082.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 2,665,676 shares of company stock valued at $10,623,569 in the last three months. Company insiders own 33.80% of the company’s stock.

Amyris Profile

(Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

Read More

Institutional Ownership by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.